Skip to main content
Jonathan Rosenberg, MD, Oncology, New York, NY

JonathanE.RosenbergMD

Oncology • New York, NY

Genitourinary Oncology

Chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center

Request Appointment

Overview of Dr. Rosenberg

Dr. Jonathan Rosenberg is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Harvard Medical School and has been in practice 20 years. Dr. Rosenberg accepts several types of health insurance, listed below. He is one of 497 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

  • University of California (San Francisco)
    University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2000 - 2003
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1997 - 2000
  • Harvard Medical School
    Harvard Medical SchoolClass of 1997

Certifications & Licensure

  • CT State Medical License
    CT State Medical License 2023 - 2026
  • NY State Medical License
    NY State Medical License 1998 - 2026
  • NJ State Medical License
    NJ State Medical License 2019 - 2025
  • PA State Medical License
    PA State Medical License 2022 - 2024
  • NC State Medical License
    NC State Medical License 2020 - 2022
  • MA State Medical License
    MA State Medical License 2008 - 2013
  • CA State Medical License
    CA State Medical License 2000 - 2009
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Enno Ercklentz Endowed Chair Memorial Sloan Kettering Cancer Center

Publications & Presentations

PubMed

Journal Articles

  • Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma  
    Jonathan E Rosenberg, Daniel P Petrylak, The New England Journal of Medicine

Lectures

  • CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with m... 
    2019 ASCO Annual Meeting - 6/1/2019
  • EV-201 Study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who pre... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Authored Content

  • ASCO 2018: Dr. Jonathan E. Rosenberg on Updated in Genitourinary OncologyJune 2018
  • ASCO 2018: Dr. Jonathan E. Rosenberg on Updated in Genitourinary OncologyJune 2018

Press Mentions

  • Response Duration After Stopping Enfortumab Vedotin in Bladder Cancer
    Response Duration After Stopping Enfortumab Vedotin in Bladder CancerNovember 15th, 2024
  • Promising OS at 5 Years with Chemo-Free Combo in Urothelial Cancer
    Promising OS at 5 Years with Chemo-Free Combo in Urothelial CancerNovember 8th, 2024
  • Real-World Data Suggest Benefit From SBRT Plus Pembro in Advanced Bladder Cancer
    Real-World Data Suggest Benefit From SBRT Plus Pembro in Advanced Bladder CancerOctober 1st, 2024
  • Join now to see all

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    BCBS Blue Card PPO
    BCBS Texas BlueChoice
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Empire BCBS HMO
    Empire BCBS PPO
    First Health PPO
    GHI PPO
    Great West PPO
    Harvard Pilgrim HMO
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PPO
    MVP Healthcare PPO
    Oxford Health Freedom
    Oxford Health Liberty
    UniCare PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment

Dr. Jonathan Rosenberg, Dr. Jonathan Rosenberg, MD, Dr. J Rosenberg, Dr. Jonathan E. Rosenberg